GlassScriptPhysician profile
Julia M Lagow
NPI 1861640823
$1,692.79
in general payments reported to CMS, 2019-2025
25 companies · $460 in 2025
The $460 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $28.46 · 2021: $61.79 · 2022: $388 · 2023: $208 · 2024: $292 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $202.77 | 2022-2025 | Veozah |
| Abbvie INC. | $176.70 | 2019-2023 | |
| Organon LLC | $170.57 | 2023-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $162.48 | 2022-2025 | |
| Hologic Sales and Service, LLC | $125.14 | 2022-2025 | Myosure Tissue Removal Device, Novasure, Thinprep 2000 Processor |
| Ucb, INC. | $105.06 | 2022 | |
| Myovant Sciences INC. | $98.80 | 2021-2022 | |
| Amgen INC. | $95.27 | 2019-2025 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $74.51 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $69.62 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $65.36 | 2019-2025 | |
| Pfizer INC. | $57.81 | 2019-2024 | |
| Sage Therapeutics, LLC | $44.04 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $40.56 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $34.36 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lsi Solutions INC | $21.89 | 2024 | Fornisee |
| Shield Therapeutics INC | $20.98 | 2022 | |
| Agile Therapeutics, INC. | $18.91 | 2022 | |
| Smith+Nephew, INC. | $18.70 | 2019 | |
| Monaghan Medical Corporation | $18.20 | 2023 | Aerochamber |
| Evofem Biosciences, INC. | $15.74 | 2022 | |
| Duchesnay USA Incorporated | $14.92 | 2019 | |
| Aesculap, INC. | $14.92 | 2019 | |
| Merck Sharp & Dohme LLC | $13.77 | 2019 | |
| Lupin INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Lagow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.